1-3 of 3
Emad Elquza, MD MBA
Close
Sort by
Journal Articles

Implementation of Outpatient High-Dose Cytarabine (HiDAC) for AML: Evaluation of the Impact of Transitioned Outpatient Chemotherapy in an Oncology Care Model Setting

Leila Jafari, Jubair Hussain, Ravi Krishnadasan, MD, Keri R Maher, DO, Faiz Anwer, MD, Emad Elquza, MD MBA, Christopher Campen, PharmD, Lauren Sanders, PharmD, Alyssa Henglefelt, PharmD, Alicia Ortega, PharmD, Ali McBride, PharmD,MS
Journal: Blood
Blood (2019) 134 (Supplement_1): 2153.
https://doi.org/10.1182/blood-2019-132121
Published: 2019
Journal Articles

Recurrent Venous Thromboembolism (VTE), Major Bleeding (MB), and Associated Cost of Treatment with Low Molecular Weight Heparin (LMWH) or Direct Oral Anticoagulant (DOAC) in High Risk Patients with Gastrointestinal (GI) Malignancies: Retrospective Real-World Analysis at a Comprehensive Cancer Center

Alejandro Recio Boiles, MD, Ali McBride, PharmD,MS, Hani M. Babiker, MD, Nimer Alsaid, PhD MS, PharmD, Ivo Abraham, PhD RN, Emad Elquza, MD MBA
Journal: Blood
Blood (2018) 132 (Supplement 1): 5057.
https://doi.org/10.1182/blood-2018-99-114204
Published: 2018
Journal Articles

Clinical Risk Factors Associated with Recurrent Venous Thromboembolism and Major Bleeding in Gastrointestinal Cancer Patients Receiving Doacs for Secondary Thromboprophylaxis

Alejandro Recio Boiles, MD, Jessica Vondrak, MD, Kristopher J. Abbate, AB, Hani M. Babiker, MD, Aaron J. Scott, MD, Ali McBride, PharmD, MS, BCPS, BCOP, Emad Elquza, MD MBA
Journal: Blood
Blood (2017) 130 (Supplement 1): 4918.
https://doi.org/10.1182/blood.V130.Suppl_1.4918.4918
Published: 2017